A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats.
Cats
Clinical effects
Feline
Oclacitinib
Pruritus
Safety
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
08 May 2019
08 May 2019
Historique:
received:
12
12
2018
accepted:
29
04
2019
entrez:
10
5
2019
pubmed:
10
5
2019
medline:
24
5
2019
Statut:
epublish
Résumé
Oclacitinib is a Janus kinase (JAK) 1 enzyme inhibitor and blocks JAK1-dependent cytokines and is used to control pruritus. Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this specie, the aim of this study was to evaluate the safety and clinical effects of oral oclacitinib maleate in healthy cats. Thirty mixed-breed cats weighing from 2.1 to 5.3 kg each were randomly allocated to three treatment groups of 10 animals each. Cats in two groups received oclacitinib at 1 mg/kg or 2 mg/kg q 12 h orally for 28 days. Cats in the third group were given placebo tablets (cornstarch) q 12 h orally for 28 days. Oclacitinib maleate was well tolerated during the study and few adverse events were observed in treated cats. Clinical signs of toxicity were not observed in any animals treated at 1 mg/kg. Gastrointestinal clinical signs observed in the 2 mg/kg group included vomiting in two of the 10 cats and soft stools in two cats. One cat treated with placebo also exhibited soft stools. No significant differences were observed between the groups for hematologic analyses performed during the study. There was a slight increase in neutrophils and monocytes and a decrease in eosinophil mean counts in treated cats. Mean renal and liver enzymes remained normal throughout the entire study. A small, but significant increase in fructosamine levels was observed for both treated groups compared with placebo; however, values remained within the normal reference range. There were no significant difference between treated groups and the placebo group for urine specific gravity, pH, or urine protein to creatinine ratio mean values. Oclacitinib maleate was well tolerated by cats at 1 mg/kg and 2 mg/kg and appeared to be safe for this species when administered orally twice daily for 28 days. More studies would be needed to demonstrate if oclacitinib maleate may be a suitable alternative to treat pruritic cats.
Sections du résumé
BACKGROUND
BACKGROUND
Oclacitinib is a Janus kinase (JAK) 1 enzyme inhibitor and blocks JAK1-dependent cytokines and is used to control pruritus. Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this specie, the aim of this study was to evaluate the safety and clinical effects of oral oclacitinib maleate in healthy cats.
RESULTS
RESULTS
Thirty mixed-breed cats weighing from 2.1 to 5.3 kg each were randomly allocated to three treatment groups of 10 animals each. Cats in two groups received oclacitinib at 1 mg/kg or 2 mg/kg q 12 h orally for 28 days. Cats in the third group were given placebo tablets (cornstarch) q 12 h orally for 28 days. Oclacitinib maleate was well tolerated during the study and few adverse events were observed in treated cats. Clinical signs of toxicity were not observed in any animals treated at 1 mg/kg. Gastrointestinal clinical signs observed in the 2 mg/kg group included vomiting in two of the 10 cats and soft stools in two cats. One cat treated with placebo also exhibited soft stools. No significant differences were observed between the groups for hematologic analyses performed during the study. There was a slight increase in neutrophils and monocytes and a decrease in eosinophil mean counts in treated cats. Mean renal and liver enzymes remained normal throughout the entire study. A small, but significant increase in fructosamine levels was observed for both treated groups compared with placebo; however, values remained within the normal reference range. There were no significant difference between treated groups and the placebo group for urine specific gravity, pH, or urine protein to creatinine ratio mean values.
CONCLUSIONS
CONCLUSIONS
Oclacitinib maleate was well tolerated by cats at 1 mg/kg and 2 mg/kg and appeared to be safe for this species when administered orally twice daily for 28 days. More studies would be needed to demonstrate if oclacitinib maleate may be a suitable alternative to treat pruritic cats.
Identifiants
pubmed: 31068210
doi: 10.1186/s12917-019-1893-x
pii: 10.1186/s12917-019-1893-x
pmc: PMC6506962
doi:
Substances chimiques
Pyrimidines
0
Sulfonamides
0
oclacitinib
99GS5XTB51
Types de publication
Clinical Trial, Veterinary
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
137Subventions
Organisme : Zoetis
ID : doanted oclacitinib tablets
Organisme : CAPES
ID : Finance code 001
Références
Vet Dermatol. 2004 Jun;15(3):194-8
pubmed: 15214957
Aust Vet J. 2006 Jan-Feb;84(1-2):30-5
pubmed: 16498831
Vet J. 2009 Apr;180(1):55-9
pubmed: 18294881
Vet Clin North Am Small Anim Pract. 2009 Nov;39(6):993-1007, v
pubmed: 19932359
J Feline Med Surg. 2011 May;13(5):364-75
pubmed: 21515223
Vet Dermatol. 2012 Oct;23(5):387-e72
pubmed: 22681547
Vet Dermatol. 2012 Oct;23(5):440-e84
pubmed: 22882582
Vet Dermatol. 2013 Oct;24(5):479-e114
pubmed: 23829933
J Feline Med Surg. 2013 Sep;15(9):778-84
pubmed: 23966004
J Vet Pharmacol Ther. 2014 Aug;37(4):317-24
pubmed: 24495176
Vet Dermatol. 2013 Dec;24(6):587-97, e141-2
pubmed: 24581322
Vet Dermatol. 2014 Dec;25(6):512-8, e86
pubmed: 25109820
Vet Dermatol. 2015 Feb;26(1):23-30, e7-8
pubmed: 25496303
Vet Dermatol. 2015 Jun;26(3):171-9, e35
pubmed: 25688708
Vet Dermatol. 2015 Aug;26(4):235-e52
pubmed: 25940959
BMC Vet Res. 2015 Nov 05;11:276
pubmed: 26542105
Vet Dermatol. 2016 Feb;27(1):34-e10
pubmed: 26666963
Vet Sci. 2017 May 09;4(2):null
pubmed: 29056684
Vet Dermatol. 2018 Apr;29(2):107-e43
pubmed: 29068099
Vet Dermatol. 2019 Apr;30(2):110-e30
pubmed: 30656750